Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M4,488Revenue $M287Net Margin (%)-26.6Z-Score9.2
Enterprise Value $M4,175EPS $-0.6Operating Margin %-27.0F-Score3
P/E(ttm))0Cash Flow Per Share $-1.2Pre-tax Margin (%)-26.6Higher ROA y-yN
Price/Book21.010-y EBITDA Growth Rate %-4.9Quick Ratio2.9Cash flow > EarningsY
Price/Sales15.55-y EBITDA Growth Rate %-12.7Current Ratio3.2Lower Leverage y-yY
Price/Cash Flow0y-y EBITDA Growth Rate %0ROA % (ttm)-16.1Higher Current Ratio y-yN
Dividend Yield %0Insider Buy (3m)1ROE % (ttm)-33.9Less Shares Outstanding y-yN
Payout Ratio %0Shares Outstanding M124ROI % (ttm)-20.8Gross Margin Increase y-yN

Gurus Latest Trades with SGEN

Number of guru portfolios checked: 84. (List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)
TickerGuruDate Action
Impactdown Price Range
(Average)*
Current Price Change from Average Comment Current Shares
SGENRay Dalio 2014-06-30 Sold Out -0.01%$32.82 - $46.79
($37.8)
$ 36.10-5%Sold Out0
SGENRay Dalio 2014-03-31 Buy 0.01%$38.57 - $55.14
($47.61)
$ 36.10-32%New holding22,400
SGENPRIMECAP Management 2011-06-30 Add0.05%$15 - $21.34
($17.98)
$ 36.1050%Add 21.21%9,572,853
SGENPRIMECAP Management 2011-03-31 Add0.04%$13.95 - $17.23
($15.41)
$ 36.1057%Add 29.25%7,897,953
SGENPRIMECAP Management 2010-12-31 Add0.06%$13.77 - $17.35
($15.64)
$ 36.1057%Add 77.80%6,110,600
SGENPRIMECAP Management 2010-09-30 Buy 0.09%$11.44 - $15.08
($12.22)
$ 36.1066%New holding3,436,800
SGENJean-Marie Eveillard 2010-03-31 Sold Out -0.01%$9.34 - $12.59
($10.84)
$ 36.1070%Sold Out0
SGENJean-Marie Eveillard 2009-12-31 Buy 0.01%$8.74 - $13.16
($9.69)
$ 36.1073%New holding67,373
SGENBill Gates 2009-09-30 Sold Out -0.39%$8.75 - $14.8
($11.69)
$ 36.1068%Sold Out0
SGENJean-Marie Eveillard 2009-06-30 Sold Out -0.01%$8.18 - $10.34
($9.08)
$ 36.1075%Sold Out0
Premium Real Time Picks are included for Premium Members only!!
*The price and date might not be the actual time and price at which the transactions were made. In the case of institutional owners, the date is stated as the last day of their fiscal quarter. The prices are estimates if no accurate information available. Foreign holdings may not be included.

SGEN is held by these Gurus:

Premium Most recent portfolio changes are included for Premium Members only!


SGEN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
Cline Darren SSVP, Commercial 2015-03-13Sell7,500$38.65-6.29view
HIMES VAUGHN BEVP, Proc Svcs & Tech Ops 2015-03-12Sell20,000$36.65-1.17view
BAKER FELIXDirector, 10% Owner 2015-03-10Buy285,036$34.664.5view
BAKER FELIXDirector, 10% Owner 2015-03-04Buy448,841$34.843.96view
BAKER FELIXDirector, 10% Owner 2015-02-25Buy281,115$33.926.78view
SIEGALL CLAY BPresident and CEO 2015-01-06Sell16,804$31.813.9view
BAKER FELIXDirector, 10% Owner 2014-12-16Buy2,883,378$31.8613.68view
BAKER FELIXDirector, 10% Owner 2014-12-10Buy1,247,896$33.827.1view
FBB3 LLCDirector, 10% Owner 2014-12-09Sell0$07.1view
HIMES VAUGHN BEVP, Tech. Ops. & Proc. Sci. 2014-11-12Sell10,000$37.52-3.46view

Press Releases about SGEN :

    Quarterly/Annual Reports about SGEN:

      News about SGEN:

      Articles On GuruFocus.com
      Seattle Genetics: Can Record Growth From Its Licenses Oct 28 2014 
      Seattle Genetics: Can Record Sustained Growth From Royalty Aug 31 2014 
      Will ImmunoGen’s Q4 Earnings Disappoint Again? Jul 30 2014 
      Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
      Comment for Companies Ranked by Business Predictability Jan 04 2013 
      Weekly CFO Sells Highlight: SGEN, PFIE, MAR, ESRX, LIOX, RGEN Sep 10 2012 
      WEEKLY CFO SELLS HIGHLIGHT: SBAC, XOXO, MTH, FICO, SGEN, OAS Sep 03 2012 
      Weekly CFO Sells Highlight: SWKS, P, SGEN, RT Jun 11 2012 
      5 Resilient Biotech Stocks to Buy for 2012 Feb 28 2012 
      Weekly CFO Sells Highlight: SGEN, APKT, AMRC, FNGN Oct 10 2011 

      More From Other Websites
      SEATTLE GENETICS INC /WA Financials Mar 06 2015
      Baker Bros. Advisors Hits the Jackpot with Pharmacyclics Inc (PCYC) Sale; Incyte Corporation (INCY)... Mar 05 2015
      10-K for Seattle Genetics, Inc. Mar 01 2015
      SEATTLE GENETICS INC /WA Files SEC form 10-K, Annual Report Feb 27 2015
      Seattle Genetics to Present at Upcoming Investor Conferences Feb 26 2015
      Seattle Genetics to Present at Upcoming Investor Conferences Feb 25 2015
      Seattle Genetics (SGEN) Filed Supplemental BLA for Adcetris - Analyst Blog Feb 19 2015
      Seattle Genetics' SEA-CD40 Enters Phase I for Solid Tumors - Analyst Blog Feb 18 2015
      Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS®... Feb 18 2015
      Seattle Genetics Submits Supplemental BLA to FDA for Phase 3 AETHERA Trial of ADCETRIS®... Feb 18 2015
      Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced... Feb 17 2015
      Seattle Genetics Advances Immuno-Oncology Program SEA-CD40 Into Phase 1 Clinical Trial for Advanced... Feb 17 2015
      Ceiling seen for Seattle Genetics Feb 12 2015
      Seattle Genetics Posts Narrower-than-Expected Loss in Q4 - Analyst Blog Feb 11 2015
      Seattle Genetics reports 4Q loss Feb 10 2015
      Seattle Genetics reports 4Q loss Feb 10 2015
      Seattle Genetics Inc Earnings Call scheduled for 4:30 pm ET today Feb 10 2015
      SEATTLE GENETICS INC /WA Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 10 2015
      Seattle Genetics Reports Fourth Quarter and Year 2014 Financial Results Feb 10 2015
      Q4 2014 Seattle Genetics Inc Earnings Release - After Market Close Feb 10 2015

      Add Notes, Comments

      If you want to ask a question, or report a bug, please create a support ticket.

      User Comments

      No comment yet
      Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
      GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
      Free 7-day Trial
      FEEDBACK